VIVOS INC Files Q3 2024 10-Q

TL;DR

VIVOS INC dropped its Q3 10-Q, check financials for the latest.

AI Summary

VIVOS INC filed its 10-Q for the period ending September 30, 2024. The company, formerly known as ADVANCED MEDICAL ISOTOPE Corp, is based in Richland, WA, and operates in the Surgical & Medical Instruments & Apparatus industry. The filing covers the third quarter and the first nine months of the fiscal year.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for VIVOS INC, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information that could reveal significant risks or opportunities, but without specific financial data in the provided text, a definitive risk level cannot be assigned.

Key Numbers

• Q3 — Quarter (Reporting period)
• 2024 — Fiscal Year (Reporting period)

Key Players & Entities

• VIVOS INC (company) — Filer
• ADVANCED MEDICAL ISOTOPE Corp (company) — Former company name
• 20240930 (date) — Period of report
• 20241113 (date) — Filing date
• 719 JADWIN AVENUE (address) — Business and mailing address
• RICHLAND, WA (location) — City and State

FAQ

Key Financial Figures

• $9 million — any believes it will cost approximately $9 million to: (1) fund the FDA approval process t

Filing Documents

• form10-q.htm (10-Q) — 1577KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 9KB
• 0001493152-24-045032.txt ( ) — 5743KB
• rdgl-20240930.xsd (EX-101.SCH) — 28KB
• rdgl-20240930_cal.xml (EX-101.CAL) — 28KB
• rdgl-20240930_def.xml (EX-101.DEF) — 153KB
• rdgl-20240930_lab.xml (EX-101.LAB) — 280KB
• rdgl-20240930_pre.xml (EX-101.PRE) — 214KB
• form10-q_htm.xml (XML) — 1077KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 Item 6. Exhibits 27

SIGNATURES

SIGNATURES 28 i PART I – FINANCIAL INFORMATION VIVOS INC CONDENSED BALANCE SHEETS SEPTEMBER 30, 2024 (UNAUDITED) AND DECEMBER 31, 2023 SEPTEMBER 30, DECEMBER 31, 2024 2023 (UNAUDITED) ASSETS Current Assets: Cash $ 1,218,160 $ 1,592,287 Accounts receivable 5,000 7,000 Prepaid expenses 21,165 10,837 Total Current Assets 1,244,325 1,610,124 TOTAL ASSETS $ 1,244,325 $ 1,610,124 LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES Current Liabilities: Accounts payable and accrued expenses $ 48,820 $ 245,004 Total Current Liabilities 48,820 245,004 Total Liabilities 48,820 245,004 Commitments and contingencies - - STOCKHOLDERS' EQUITY Preferred stock, par value, $ 0.001 , 20,000,000 shares authorized, Series A Convertible Preferred, 5,000,000 shares authorized, 2,071,007 shares issued and outstanding, respectively 2,071 2,071 Additional paid in capital - Series A Convertible preferred stock 8,842,458 8,842,458 Series B Convertible Preferred, 5,000,000 shares authorized, 200,363 shares issued and outstanding, respectively 200 200 Additional paid in capital - Series B Convertible preferred stock 290,956 290,956 Series C Convertible Preferred, 5,000,000 shares authorized, 385,302 shares issued and outstanding, respectively 385 385 Preferred stock value 385 385 Additional paid in capital - Series C Convertible preferred stock 500,507 500,507 Additional paid in capital 500,507 500,507 Common stock, par value, $ 0.001 , 950,000,000 shares authorized, 417,592,703 and 387,894,033 issued and outstanding, respectively 417,593 387,894 Additional paid in capital - common stock 75,479,376 73,791,430 Accumulated deficit ( 84,338,041 ) ( 82,450,781 ) Total Stockholders' Equity 1,195,505 1,365,120 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,244,325 $ 1,610,124 1 VIVOS INC CONDENSED FOR THE NINE AND THREE MONTHS ENDE

Business

Business Overview The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (" SMSC "). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of 950,000,000 shares of common stock ("Common Stock"), $ 0.001 par value per share, and 20,000,000 shares of preferred stock ("Preferred Stock"), $ 0.001 par value per share. Our principal place of business is located at 1030 North Center Parkway, Kennewick, WA 99336. Our telephone number is (509) 222-2222. Our corporate website address is http://www.radiogel.com. Our Common Stock is currently quoted on the OTC Pink Marketplace under the symbol "RDGL." The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel , for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company's development efforts. The Company's overall vision is to globally empower physicians, medical researchers, and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (" FDA ") Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classificatio

View Full Filing

View this 10-Q filing on SEC EDGAR